These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 33658762)

  • 41. Erratum: How Can We Best Diagnose Severity Levels of Dry Eye Disease: Current Perspectives [Corrigendum].
    Clin Ophthalmol; 2023; 17():2371-2372. PubMed ID: 37600149
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease.
    Keating GM
    Drugs; 2017 Feb; 77(2):201-208. PubMed ID: 28058622
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of Retinol Palmitate on Corneal and Conjunctival Mucin Gene Expression in a Rat Dry Eye Model After Injury.
    Tabuchi N; Toshida H; Koike D; Odaka A; Suto C; Ohta T; Murakami A
    J Ocul Pharmacol Ther; 2017; 33(1):24-33. PubMed ID: 28009531
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Corrigendum: The Efficacy and Safety of Qiming Granule for Dry Eye Disease: A Systematic Review and Meta-Analysis.
    Yang M; Hu Z; Yue R; Yang L; Zhang B; Chen Y
    Front Pharmacol; 2020; 11():597639. PubMed ID: 33362551
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and efficacy of topical azithromycin ophthalmic solution 1.0% in the treatment of contact lens-related dry eye.
    Nichols JJ; Bickle KM; Zink RC; Schiewe MD; Haque RM; Nichols KK
    Eye Contact Lens; 2012 Mar; 38(2):73-9. PubMed ID: 22157392
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diquafosol ophthalmic solution 3 %: a review of its use in dry eye.
    Keating GM
    Drugs; 2015 May; 75(8):911-22. PubMed ID: 25968930
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Erratum: Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies [Corrigendum].
    Neuropsychiatr Dis Treat; 2021; 17():1481. PubMed ID: 34040374
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Erratum: Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study [Corrigendum].
    Int J Chron Obstruct Pulmon Dis; 2017; 12():231. PubMed ID: 28138232
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Erratum: The efficacy and safety of add-on 0.1% brimonidine tartrate preserved with sodium chlorite in on-treatment Japanese normal-tension glaucoma patients [Corrigendum].
    Clin Ophthalmol; 2015; 9():1365. PubMed ID: 26229429
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Erratum: The efficacy and safety of add-on 0.1% brimonidine tartrate preserved with sodium chlorite in on-treatment Japanese normal-tension glaucoma patients [Corrigendum].
    Clin Ophthalmol; 2015; 9():453. PubMed ID: 25834381
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Erratum: The Risks of miRNA Therapeutics: In a Drug Target Perspective [Erratum].
    Drug Des Devel Ther; 2021; 15():1423. PubMed ID: 33833501
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.
    Barber LD; Pflugfelder SC; Tauber J; Foulks GN
    Ophthalmology; 2005 Oct; 112(10):1790-4. PubMed ID: 16102833
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.
    Sall K; Stevenson OD; Mundorf TK; Reis BL
    Ophthalmology; 2000 Apr; 107(4):631-9. PubMed ID: 10768324
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Erratum: Assessment of safety and efficacy of lamotrigine over the course of 1-year observation in Japanese patients with bipolar disorder: post-marketing surveillance study report [Corrigendum].
    Neuropsychiatr Dis Treat; 2017; 13():2219. PubMed ID: 28860779
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Erratum: Medicine, Volume 95, Issue 23: Erratum.
    Medicine (Baltimore); 2016 Jul; 95(28):e0916. PubMed ID: 31265603
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Erratum: The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies [Corrigendum].
    Int J Chron Obstruct Pulmon Dis; 2020; 15():1177. PubMed ID: 32581524
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study.
    Donnenfeld ED; Karpecki PM; Majmudar PA; Nichols KK; Raychaudhuri A; Roy M; Semba CP
    Cornea; 2016 Jun; 35(6):741-8. PubMed ID: 27055211
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Erratum: Continuous Wound Infiltration of Local Anesthetics in Postoperative Pain Management: Safety, Efficacy and Current Perspectives [Corrigendum].
    J Pain Res; 2020; 13():659. PubMed ID: 32280267
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lifitegrast: a novel drug for patients with dry eye disease.
    Haber SL; Benson V; Buckway CJ; Gonzales JM; Romanet D; Scholes B
    Ther Adv Ophthalmol; 2019; 11():2515841419870366. PubMed ID: 31489402
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye.
    Tauber J; Davitt WF; Bokosky JE; Nichols KK; Yerxa BR; Schaberg AE; LaVange LM; Mills-Wilson MC; Kellerman DJ
    Cornea; 2004 Nov; 23(8):784-92. PubMed ID: 15502479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.